Cognition Therapeutics, Inc. (NASDAQ:CGTX – Free Report) – Equities research analysts at Brookline Capital Management issued their FY2024 earnings estimates for shares of Cognition Therapeutics in a report released on Monday, January 27th. Brookline Capital Management analyst T. Bussian anticipates that the company will post earnings per share of ($0.83) for the year. Brookline Capital Management currently has a “Strong-Buy” rating on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.86) per share. Brookline Capital Management also issued estimates for Cognition Therapeutics’ Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.15) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.40) EPS and FY2025 earnings at ($0.95) EPS.
Several other research analysts also recently issued reports on CGTX. B. Riley upgraded shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the stock from $1.00 to $1.50 in a report on Thursday, December 19th. HC Wainwright upped their target price on Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Thursday, December 19th. Finally, Chardan Capital reissued a “buy” rating and set a $11.00 price target on shares of Cognition Therapeutics in a research note on Thursday, December 19th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Cognition Therapeutics currently has an average rating of “Buy” and a consensus price target of $8.30.
Cognition Therapeutics Price Performance
Shares of NASDAQ:CGTX opened at $0.76 on Wednesday. Cognition Therapeutics has a one year low of $0.34 and a one year high of $2.95. The company has a market cap of $31.61 million, a price-to-earnings ratio of -0.78 and a beta of 0.95. The firm has a 50 day simple moving average of $0.61 and a 200 day simple moving average of $0.69.
Institutional Investors Weigh In On Cognition Therapeutics
Large investors have recently modified their holdings of the company. SG Americas Securities LLC acquired a new stake in Cognition Therapeutics during the 4th quarter worth about $26,000. Virtu Financial LLC bought a new stake in shares of Cognition Therapeutics during the 3rd quarter valued at about $27,000. Sigma Planning Corp boosted its position in shares of Cognition Therapeutics by 14.6% during the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after purchasing an additional 25,050 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV grew its stake in Cognition Therapeutics by 33.4% during the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after purchasing an additional 24,050 shares during the period. 43.35% of the stock is currently owned by institutional investors and hedge funds.
About Cognition Therapeutics
Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.
Featured Articles
- Five stocks we like better than Cognition Therapeutics
- Stock Splits, Do They Really Impact Investors?
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- NYSE Stocks Give Investors a Variety of Quality Options
- 3 Steel Stocks Soaring After Tariff Announcements
- Options Trading – Understanding Strike Price
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Cognition Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognition Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.